Lesbians’ Rights and Cancer

Lesbian, Bisexual, and Transgender women with Cancer have the:

1. Right to the provision of sensitive, culturally appropriate care that is not diminished, altered or impacted by biases, stereotypes or assumptions held by providers. In addition, LBT women with cancer should have access to providers trained in lesbian, bisexual, and transgender cultural competency and who are knowledgeable about the specific health care needs of LBT patients.

2. Right to not suffer repercussions from disclosing pertinent information about their sexual orientation, behavior or identity. While it is expected that health care providers be receptive and sensitive to cultures and lifestyles different from their own, this is often not the case. Negative views toward homosexuality, should not, in any way, interfere with the provision of quality care to LBT women with cancer. No patient should be denied health care services, nor be treated in an unprofessional, discourteous or demeaning manner because of disclosure of their sexual orientation and nor should there be assumptions made about their sexual orientation or behavior.

  • For more information, please contact Mautner Project,
  • The National Lesbian Health
  • Organization
  • 1875 Connecticut Ave., NW
  • Suite 710
  • Washington, DC 20009
  • [ t ] 202 332 5536
  • [ f ] 202 332 0662
  • [toll-free] 1-866-MAUTNER (1-866-628-8637)
Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap